ProCE Banner Activity

PHERGain: 3-Yr iDFS Results From the Phase II Trial of Chemotherapy De‑escalation in HER2+ Early Breast Cancer

Conference Coverage
Slideset

In patients with HER2+ EBC treated according to a PET-based, response-adapted strategy, 3-year iDFS was 95.4%, with a 3-year iDFS of 98.8% among patients with PET response and pCR treated solely with pertuzumab/trastuzumab and no chemotherapy.

Released: June 04, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.